X-BOLT Orthopaedics, a leading medical device company, today announced preliminary results from the largest ever multi-centre randomised controlled trial comparing extracapsular hip fracture fixation devices, known as World Hip Trauma Evaluation 4 (WHITE4). The trial...
First Phase 3 Study Combining KYPROLIS and DARZALEX, Two Critical Mechanisms of Action in Treatment of Multiple Myeloma Amgen (NASDAQ:AMGN) today announced the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with dexamethasone and...
Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that it will present updated clinical results from the Phase 2b clinical trial of MDNA55 for the...
Sept. 12, 2019 13:07 UTC The 100+ site global Phase 3 clinical trial is the first-of-its-kind to leverage continuous multivariate wearable sensor data and Artificial Intelligence-based analytics The landmark trial endpoint approach aligns with commentary at a recent...
PALO ALTO, Calif., Sept. 12, 2019 /PRNewswire/ — SightGlass Vision, Inc., a medical device company developing spectacle lenses to slow the progression of nearsightedness or myopia in children, today announced that baseline data from CYPRESS, the Company’s...
Combination of Novel Gene Therapy and Immunotherapy Being Evaluated for Synergistic Anti-Tumor Activity in Patients with Cancer with Limited Treatment Options Okayama, Japan, (GLOBE NEWSWIRE) – Momotaro-Gene, a clinical-stage biotherapeutics company developing...
Email
Text